{"name":"XenoPort, Inc.","slug":"xenoport-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Sinemet (comparator)","genericName":"Sinemet (comparator)","slug":"sinemet-comparator","indication":"Parkinson's disease","status":"marketed"},{"name":"XP13512 (GSK1838262)","genericName":"XP13512 (GSK1838262)","slug":"xp13512-gsk1838262","indication":"Partial-onset seizures","status":"phase_3"},{"name":"GEn (XP13512)","genericName":"GEn (XP13512)","slug":"gen-xp13512","indication":"Postherpetic neuralgia","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"GSK1838262 600 mg","genericName":"GSK1838262 600 mg","slug":"gsk1838262-600-mg","indication":"Other","status":"marketed"},{"name":"GSK1838262 Placebo match","genericName":"GSK1838262 Placebo match","slug":"gsk1838262-placebo-match","indication":"Other","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"GSK1838262 Extended Release Tablets","genericName":"GSK1838262 Extended Release Tablets","slug":"gsk1838262-extended-release-tablets","indication":"Type 2 diabetes mellitus","status":"phase_3"}]}],"pipeline":[{"name":"Sinemet (comparator)","genericName":"Sinemet (comparator)","slug":"sinemet-comparator","phase":"marketed","mechanism":"Sinemet combines levodopa (a dopamine precursor) with carbidopa (a decarboxylase inhibitor) to increase dopamine levels in the brain while preventing peripheral conversion of levodopa.","indications":["Parkinson's disease","Parkinsonism secondary to carbon monoxide poisoning or manganese intoxication"],"catalyst":""},{"name":"XP13512 (GSK1838262)","genericName":"XP13512 (GSK1838262)","slug":"xp13512-gsk1838262","phase":"phase_3","mechanism":"XP13512 is a voltage-gated sodium channel blocker.","indications":["Partial-onset seizures"],"catalyst":""},{"name":"GEn (XP13512)","genericName":"GEn (XP13512)","slug":"gen-xp13512","phase":"phase_3","mechanism":"XP13512 is a prodrug of gabapentin that uses a novel amino acid transporter-mediated delivery system to enhance absorption and bioavailability in the gastrointestinal tract.","indications":["Postherpetic neuralgia","Diabetic peripheral neuropathy"],"catalyst":""},{"name":"GSK1838262 600 mg","genericName":"GSK1838262 600 mg","slug":"gsk1838262-600-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GSK1838262 Extended Release Tablets","genericName":"GSK1838262 Extended Release Tablets","slug":"gsk1838262-extended-release-tablets","phase":"phase_3","mechanism":"GSK1838262 is a selective inhibitor of sodium-dependent glucose cotransporter 1 (SGLT1) that reduces intestinal glucose absorption.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"GSK1838262 Placebo match","genericName":"GSK1838262 Placebo match","slug":"gsk1838262-placebo-match","phase":"marketed","mechanism":"GSK1838262 is a placebo match formulation designed to mimic the appearance and administration of an active pharmaceutical agent for use in blinded clinical trials.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPTWpJNVR4dzBqNzhSbjRNMU1YSXc4TjVxeE1OVmRpQnNpM2RDOHgyZ2VfeVVIVWMzdGFTX1luemhsVklJd1RPTFNuSnRFSmVia0o1OWZEYlNDc1FfLVV5X2F0bWZPbFFtZENqTDItNU1WblBfaHgwcmVCaVA5MVVXbzlqTmtsVHJsMUlNTA?oc=5","date":"2025-12-11","type":"pipeline","source":"Legacy","summary":"William Harris Obituary (2025) - Arroyo Grande, CA - San Francisco Chronicle - Legacy","headline":"William Harris Obituary (2025) - Arroyo Grande, CA - San Francisco Chronicle","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNcmgyQkthOFloZXI1UVpxbkdBTDBkczNTQkE5RkRMZTNnQlZMSWI4V3lVbWQySi15SHVDMGZpUWxVWW56X2RhTG1XSkdtREF3MjJDNjBKWXc0RVBQZGdJel83QkNZcG5XeFhTMW1EOGQ5V3ZkNGtmZjRUMW96M1lPOU5ES0d4dTd3X1hJc0p0aUpiWGQzaERlbHAtSjBmdllIbW1oUDdQejU4T3ZacTd1RkFmcHZ6MXd0LUxlbTRXbw?oc=5","date":"2025-12-03","type":"pipeline","source":"Stock Titan","summary":"Soleno Therapeutics (NASDAQ: SLNO) Announces Passing of Director, New Audit Chair - Stock Titan","headline":"Soleno Therapeutics (NASDAQ: SLNO) Announces Passing of Director, New Audit Chair","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE5ZMTJtcjZOb0Jwc0E2ZjJ5YTBITGtucE45NFRhN0dIbC1Zam1sU004bWxlNk9KbnNFcmN6QUEzRlctMWpGR28wME1ZSEQyeFNBZHRIY0kyR1EzaFVGMnRxVW9HZXpUT0Q2ZjFWWURfbk5GSUgxVkE?oc=5","date":"2024-07-17","type":"pipeline","source":"The Pharma Letter","summary":"Arbor Pharmaceuticals - The Pharma Letter","headline":"Arbor Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQMVktWkJSNF9Bb05rbTdMWWNjZl9WaF9jcXR4MUlkeU9OZUxTcHRLSkY5VUNSM0JKS2pCWVZ1cldKQ2NyZzZjV0xKbFNRaDg4WDNBXzQwQ0lXb1FiM3BiVmpfZ0s2cy01T04wOHRSR0ctY1BWVlBwYTFMOFZOM1J0NlowZ0pQMHZuTFZ3UTltSUxRRHZmaE1uM29lcndmaDJsZkhlVkpoUW5HLTFNTUFFYTE5SUNWRWN4TW1DUkFn?oc=5","date":"2024-02-26","type":"pipeline","source":"Healio","summary":"Applying moisturizer before HP/TAZ for psoriasis may improve tolerability - Healio","headline":"Applying moisturizer before HP/TAZ for psoriasis may improve tolerability","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPemtNZlp6Um0xUXlJenliczlGQXpxeDdGSXBzOUd3RWY2MnF6clVTcXVoZ09uSXQzQnZSeFVoenFzV1dPOXRKTFNIZVBFMmtqNGN3TC1FajNoaC1CeVhMRE16Nm9KVkdLa2FtbmkzNXBvR09RaVV1elA2bTlfQTNvNGRKNU5TX25mVXpDUGpXTmx3TmJEN0QwWGptOXd3c3lOdDUwRlg3Z095RHBLcHJuaUR6MnZBd19kWTNWRndVS0JvQQ?oc=5","date":"2023-05-16","type":"pipeline","source":"Pharmacy Times","summary":"Taking Gabapentin With Opioids for Acute Conditions Increases Risk of Opioid-Use Disorder - Pharmacy Times","headline":"Taking Gabapentin With Opioids for Acute Conditions Increases Risk of Opioid-Use Disorder","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE5xdmdLU2JWN29RXzU1ZjJPbms3UUM5WUZsRHlZNnlZNjhXcDdETGVzRXR3MzhsdEs3NTVTazNJeHp4TnJ5M3N5WnZ0dVVSZUVOR24tSkY4LVgtMzBsY3ZndEtKRm8?oc=5","date":"2021-09-15","type":"pipeline","source":"National Today","summary":"RESTLESS LEGS AWARENESS DAY - September 23, 2026 - National Today","headline":"RESTLESS LEGS AWARENESS DAY - September 23, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPSmxpWEhNUzdfR2xUejFTRXA5dDVSdjhLQ1B1WU1wOXJBVVhSWDhyTER6RFc2c2JOMjh6amxuX1ZTNlhuN19iYl9YRXZlTjlkSWV1QkFwM2t4ZVpDWWlwNTF4R3VacS1KeE4tQ1p4THZrY2p1cXJ2d0kza29GOFJXeklsejh5ZkREOTVkRk1adEVibzZRYm5PcUh2YmZXcktjVkhULVZoTm83LWxyZE1acThIVU5KMkVlS0I2c1FLcXhwaDhoZC11Rk85YW1UU0Q2cGU0MFFKN1I1N0hqcl9uaTZIaVRzeGVh?oc=5","date":"2016-09-20","type":"pipeline","source":"prnewswire.com","summary":"Dermata Therapeutics, LLC Announced the Addition of Wendell Wierenga, Ph.D. to its Board of Directors - prnewswire.com","headline":"Dermata Therapeutics, LLC Announced the Addition of Wendell Wierenga, Ph.D. to its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNbVJQbmV0R0FqenpvR25CU0owaXlJRWxBVzEwRVgzNGVkRlFFMnNqeFk1MWt2c3NUXzE5bWpvX29TVGR6dTlWSEo0Vk5mVVlHdXQ1b2llRThBOXJFR0NCa1BhNmpfaElCZnFDRktBZWJ2RmJ0M09ZcmY4OVpPbnFPYnY3V0h4MENLZXAtU3N3?oc=5","date":"2016-05-24","type":"deal","source":"BioPharma Dive","summary":"Arbor Pharma buys XenoPort for $467 million - BioPharma Dive","headline":"Arbor Pharma buys XenoPort for $467 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOS1dYYnp1Q2xidERIeUpKaExieERjU1k3Y3dFQ1BzSTdRUFVPX2pENEdscTdGVGRTdVJfOEVOdFVJVjN3TmIySnFlLTJhNnZLTUhsR3hjcG4xamFFVFpleTVBYXlQUGhDbEh4NFNURlZxSUQ0VFdoUnNGUWUwaVVGVGdGd19hb0wzeC1jbGtCTlB2Wm91R3Vndy1EQkpDc19OdUE?oc=5","date":"2016-05-23","type":"deal","source":"Fierce Biotech","summary":"Arbor buys out struggling Horizant developer XenoPort for $467M - Fierce Biotech","headline":"Arbor buys out struggling Horizant developer XenoPort for $467M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOb05nTjdaWHZ5SGRocHBWYlpRMGR1dTZELW9iX2lKTWtVVEZxZ3VnWTAxZDVuUEtreXBDOEx5QWFhRThyd3BZcUNoRDVrLUxxbTZWOXNxVGdza24xekVNbG05WVpiT0l4eGhkZVpDNUx5eU04dXgyaG1fWGRoZDFic1ZtV3NYbzZqeXJ3Wm5DTGhHbURQcjE1dXh3QXdabm1wdFJacUFRNDVsemZMSUdOcmd5dw?oc=5","date":"2015-10-22","type":"pipeline","source":"MDedge.com","summary":"BEST PRACTICES: An Oral Treatment for Moderate to Severe Plaque Psoriasis - MDedge.com","headline":"BEST PRACTICES: An Oral Treatment for Moderate to Severe Plaque Psoriasis","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"marketed":3,"phase_3":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}